COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03969420
Recruitment Status : Recruiting
First Posted : May 31, 2019
Last Update Posted : July 24, 2020
Information provided by (Responsible Party):
Sumitomo Dainippon Pharma Oncology, Inc

Brief Summary:
This study will evaluate the safety and efficacy of alvocidib in patients with AML who have either relapsed from or are refractory to venetoclax in combination with azacytidine or decitabine.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia (AML) Drug: Alvocidib (flavopiridol) and cytarabine (Ara-C) Drug: Alvocidib (flavopiridol) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 128 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, Two-stage
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
Actual Study Start Date : January 15, 2020
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : July 2023

Arm Intervention/treatment
Experimental: Stage 1: Arm 1
Refractory (i.e., failed to achieve a CR/CRi or achieved a CR/CRi with duration <90 days)
Drug: Alvocidib (flavopiridol) and cytarabine (Ara-C)
Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection

Experimental: Stage 1: Arm 2
Relapsed (i.e., reoccurrence of disease following a CR/CRi with duration ≥90 days).
Drug: Alvocidib (flavopiridol)
Administered intravenously

Primary Outcome Measures :
  1. Rate of combined complete remission (complete remission (CR) + CR with incomplete hematological recovery (CRi)), as defined by the International Working Group Criteria and 2017 European LeukemiaNet) [ Time Frame: 18 months ]

Secondary Outcome Measures :
  1. Median overall survival. [ Time Frame: 42 months ]
  2. CR rate [ Time Frame: 18 months ]
  3. Composite CR rate - Combined CR + CRi + CRh (CR + partial recovery of both blood cell types) [ Time Frame: 18 months ]
  4. Combined Response Rate - CR + CRi + CRh + MLFS (Morphologic leukemia-free state) + PR (partial response) [ Time Frame: 18 months ]
  5. EFS (Event-free survival) defined as the time from first treatment (Day 1) until (a) treatment failure, (b) relapse after CR, /CRi, or CRh or (c) death from any cause, whichever occurs first, censored at 2 years [ Time Frame: 42 months ]
  6. Duration of composite CR, defined as the time from first documented response of CR, CRi or CRhi to relapse or death from any cause [ Time Frame: 18 months ]
  7. Rates of 28- and 56-day Transfusion Independence (TI) = Percentages of patients who do not receive red blood cell (RBC) transfusions, platelet (PLT) transfusions, and neither RBC nor PLT transfusions for 28 and 56 days; comprised of 6 secondary endpoints [ Time Frame: 44 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Be ≥18 years of age.
  2. Have an established, pathologically confirmed diagnosis of AML by World Health Organization (WHO) criteria, excluding acute promyelocytic leukemia (APL-M3) with a bone marrow of >5% blasts based on histology or flow cytometry.
  3. Have received initial induction therapy with venetoclax in combination with azacytidine or decitabine and were either refractory (failed to achieve a CR/CRi or achieved a CR/CRi with duration <90 days) or have relapsed (reoccurrence of disease following a CR/CRi with duration ≥90 days).
  4. Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2.
  5. Have a glomerular filtration rate (GFR) ≥30 mL/min using the Cockcroft-Gault equation.
  6. Have an alanine aminotransferase (ALT)/aspartate aminotransferase (AST) level ≤5 times upper limit of normal (ULN).
  7. Have a total bilirubin level ≤2.0 mg/dL (unless secondary to Gilbert syndrome, hemolysis, or leukemia).
  8. Be infertile or agree to use an adequate method of contraception:sexually active patients and their partners must use an effective method of contraception associated with a low failure rate prior to study entry, for the duration of study participation, and for at least 3 months (males) and 6 months (females) after the last dose of study drug.
  9. Be able to comply with the requirements of the entire study.
  10. Provide written informed consent prior to any study related procedure: in the event that the patient is re-screened for study participation or a protocol amendment alters the care of an ongoing patient, a new informed consent form must be signed.

Exclusion Criteria:

  1. Received any previous treatment with alvocidib or any other CDK inhibitor or received prior anti-leukemic therapy other than first-line venetoclax in combination with azacytidine or decitabine.
  2. Require concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within 12 hours) of starting treatment on either arm.
  3. Received an allogeneic stem cell transplant within 60 days of the start of study treatment. Patients who received an allogeneic stem cell transplant must be off all immunosuppressants at the time of study treatment
  4. Are receiving or have received systemic therapy for graft-versus-host disease.
  5. Have a peripheral blast count of >30,000/mm3 (may use hydroxyurea as in #2 above).
  6. Received antileukemic therapy within the last 3 weeks (with the exception of hydroxyurea or if the patient has definite refractory disease). Refractory patients who received therapy within the last 3 weeks may be eligible with prior approval of the Medical Monitor.
  7. Diagnosed with acute promyelocytic leukemia (APL-M3).
  8. Have active central nervous system (CNS) leukemia.
  9. Have evidence of uncontrolled disseminated intravascular coagulation.
  10. Have an active, uncontrolled infection.
  11. Have other life-threatening illness.
  12. Have other active malignancies requiring treatment or diagnosed with other malignancies within the last 6 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia.
  13. Have mental deficits and/or psychiatric history that may compromise the ability to give written informed consent or to comply with the study protocol.
  14. Are pregnant and/or nursing.
  15. Have received any live vaccine within 14 days prior to first study drug administration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03969420

Layout table for location contacts
Contact: Reyna Bishop, MS, RD 512-363-8755
Contact: Susan Smith, MSN 210-414-7702

Layout table for location information
United States, California
Community Medical Providers Recruiting
Clovis, California, United States, 93611
Contact: Haifaa Abdulhaq, MD         
Principal Investigator: Haifaa Abdulhaq, MD         
United States, Florida
Orlando Health, Inc, Univ of Florida Health Cancer Center Recruiting
Orlando, Florida, United States, 32806
Contact: Julio Hajdenberg, MD         
Principal Investigator: Julio Hajdenberg, MD         
United States, Kansas
University of Kansas Medical Center Recruiting
Westwood, Kansas, United States, 66205
Contact: Heather Male, MD         
Principal Investigator: Heather Male, MD         
United States, Louisiana
Ochsner Medical Center Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Andrew Dalovisio, MD         
Principal Investigator: Andrew Dalovisio, MD         
United States, New Mexico
University of New Mexico Recruiting
Albuquerque, New Mexico, United States, 87106
Contact: Matthew Fero, MD         
Principal Investigator: Matthew Fero, MD         
United States, New York
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact: Eunice Wang, MD         
Principal Investigator: Eunice Wang, MD         
Columbia University Medical Center Not yet recruiting
New York, New York, United States, 10027
Contact: Daniel Lee, MD         
Principal Investigator: Daniel Lee, MD         
United States, North Carolina
University of North Carolina (UNC) Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Erika Moore         
Principal Investigator: Joshua Zeidner, MD         
United States, Ohio
Ohio State University Not yet recruiting
Columbus, Ohio, United States, 43210
Contact: Bhavana Bhatnagar, MD         
Principal Investigator: Bhavana Bhatnagar, MD         
United States, Pennsylvania
Allegheny Health Network Recruiting
Pittsburgh, Pennsylvania, United States, 15212
Contact: Salman Fazal, MD         
Principal Investigator: Salman Fazal, MD         
United States, Texas
Baylor University Center Recruiting
Dallas, Texas, United States, 75211
Contact: Micah Burch, MD         
Principal Investigator: Micah Burch, MD         
United States, Washington
University of Washington Recruiting
Seattle, Washington, United States, 98195
Contact: Pamela Becker, MD         
Principal Investigator: Pamela Becker, MD         
Sponsors and Collaborators
Sumitomo Dainippon Pharma Oncology, Inc
Layout table for investigator information
Study Director: Stephen Anthony, DO Sumitomo Dainippon Pharma Oncology, Inc
Layout table for additonal information
Responsible Party: Sumitomo Dainippon Pharma Oncology, Inc Identifier: NCT03969420    
Other Study ID Numbers: TPI-ALV-202
First Posted: May 31, 2019    Key Record Dates
Last Update Posted: July 24, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sumitomo Dainippon Pharma Oncology, Inc:
Tolero, Phase 2, AML, Relapsed, Refractory, Alvocidib, Venetoclax
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Growth Inhibitors
Growth Substances
Protein Kinase Inhibitors
Enzyme Inhibitors